The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging. The term was developed after thousands of autopsies, numerous discoveries and significant research linked asbestos to a deadly form of cancer. As X-ray technology developed further, the framework for diagnosis and understanding the pathology of mesothelioma was established in 1931.

Over the last decade, the impact of dense fibroglandular breast tissue on breast cancer screening has become a prominent topic of national conversation among those fighting the disease. Screening is the first line of defense for patients, and the realization that their mammography results may not be accurate has caused concern. While mammography remains the gold standard for breast cancer detection and diagnosis, the “one-size-fits-all” approach of years past has evolved as patients and providers drive toward more personalized screening programs. While several technologies and other new developments have propelled this idea forward, automated breast ultrasound (ABUS) has gone a long way toward cementing the idea of patient-specific breast cancer screening protocols and programs.

The continuum of personalized care, covering individualized prevention and therapy, translates into multiple changes to patient data sources. One of the primary sources is medical imaging that evolves into various multimodalities, allowing simultaneous acquisition of clinical images. Positron emission tomography/computed tomography (PET/CT) systems have been around for more than a decade, and now PET/magnetic resonance imaging (MRI) scanners are working to reach the market.